Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients
48% fibrosis improvement of at least one stage without worsening of NAS across all dose groups, with a 62% response rate for the 50mg dose group
28% fibrosis improvement of at least two stages across all dose groups, with a 38% response rate for the 50mg dose group
48% NASH resolution without worsening of fibrosis across all dose groups, with a 54% response rate for the 50mg dose group
ir.akerotx.com/news-releases/news-release-details/akero-announces-strongly-positive-histological-data-across-all
48% fibrosis improvement of at least one stage without worsening of NAS across all dose groups, with a 62% response rate for the 50mg dose group
28% fibrosis improvement of at least two stages across all dose groups, with a 38% response rate for the 50mg dose group
48% NASH resolution without worsening of fibrosis across all dose groups, with a 54% response rate for the 50mg dose group
ir.akerotx.com/news-releases/news-release-details/akero-announces-strongly-positive-histological-data-across-all
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。